Annual Development Reports. During the period beginning on the Signature Date and continuing until the commercial launch of the first Licensed Product, Otonomy shall provide annual written reports to DURECT summarizing material development and regulatory activities undertaken by Otonomy with respect to the Licensed Products. All such reports shall be provided to DURECT strictly for information purposes only and all information contained therein shall be treated as Otonomy’s Confidential Information in accordance with Article 11.
Annual Development Reports. Akriveia will submit to WuXi a written annual report summarizing the work undertaken during the year to develop any Products under this License Agreement with the first such annual report due on [**]. Thereafter, the report must be submitted within [**] after the end of each calendar year.
Annual Development Reports. Before the first commercial sale of a LICENSED PRODUCT, LICENSEE will submit to INSTITUTE annual reports on June 30 of each year as to LICENSEE'S activities, progress and plans applicable to Paragraphs 3.1 and 3.2.
Annual Development Reports. Within [**] of finalizing and approving an early Development plan for a Collaboration Product, Schering-Plough will provide a summary of the plan to Lexicon. Thereafter, Schering-Plough will provide Lexicon with an annual report on the progress under such plan and projections for the Development plan for the upcoming year, such reports to be the Confidential Information of Schering-Plough. Lexicon shall have the reciprocal obligations for any Reverted Product.
Annual Development Reports. Company will provide to Licensor, each time within ninety (90) days after the end of a Calendar Year, with a written report in English language and in a form reasonably acceptable to Licensor, summarizing in reasonable detail the Development activities conducted by Company (itself or through its Affiliates and Sublicensees and its or their Third Party service providers) in the preceding year. Such reports shall include at least the information set forth in Schedule 4.1.b).
Annual Development Reports. The JDT shall submit annual reports with respect to the Development of Antibody Products for Agreed Indications to the Collaboration Committee as part of each annual recommended update to the Development Plan with respect to Agreed Indications. The Continuing Party with respect to an Independent Indication shall submit annual reports with respect to the Development of Antibody Products for such Independent Indication to the Collaboration Committee. Each such report shall include non-binding forecasts of the Parties’ requirements of Clinical Supplies of Antibody Products, placebo and comparators for Agreed Indications and Independent Indications (which forecasts shall be provided by the applicable Continuing Party) for the Territory for the then current year and the following [***] [Confidential Treatment Required] and any other related information that the JDT determines, or is requested by the Collaboration Committee, to include.
